The importance of immunology in tumor response to radiotherapy represents a major opportunity for our discipline. Novel therapies have emerged which target the immune cells. Combinations of such therapies to radiotherapy might translate into better local tumor control rates and also into better distant control given the possibility to use radiotherapy as an immunological enhancer of the anti-tumor immune response. Drugs targeting the immune checkpoints such as PD-1, PD-L1, and CTLA-4 blockers are among the first agents; moreover, several other agents are also in development. Thus, the selection of the optimal combination based on a sound rationale and proper patient selection will be key.
Partner’s website and additional information: http://www.radio-immuno.siricsocrate.fr/
Poster Abstract Format (submission period closed)
- NO phone numbers, hyperlinks, keyword lists, or figures.
- Maximum of 500 words (not including title and authors).
- Paragraph breaks between Title, Author & Institute, abstract body, funding and references
- Include: Background, Brief methods, Results and Conclusions
- File must be saved as Word file
- Arial, 11 point, black font
- For Greek and Scientific symbols, use the Symbol option under the Insert tab in Microsoft Word (or equivalent option in other applications)
- Single spacing, one-inch margins, left justified
- One abstract per submitting author per meeting. Presenting author must be underlined.
Please indicate if the abstract presenter is a student/post-doc or resident. Abstracts submitted by student/post-doc or residents will be reviewed by a special committee and the best abstract
In two categories, Basic/Translational and Clinical research will receive a travel award of $500 (the award will be announced at the meeting during the poster session).
As of 9/12/17 at 3 pm Eastern time, the 2017 conference has sold out. If you are interested in being notified of registration cancellations; please contact Jane Yuen at Jay2009@med.cornell.edu
For information on the 2018 Conference, please visit http://www.radio-immuno.siricsocrate.fr/en/
THURSDAY, September 21st, 2017
Lewis C. Cantley, PhD; Gary Koretzky, MD, PhD
Weill Cornell Medical College, NY, USA
Silvia Formenti, MD
Weill Cornell Medical College, NY, USA
Karolina Palucka, MD, PhD
The Jackson Laboratory, CT, USA
Alan Frey, PhD
New York University, School of Medicine, NY, USA
Charles Drake, MD, PhD
Columbia University Medical Center, NY, USA
Timothy A. Chan, MD
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Michael Postow, MD
Memorial Sloan Kettering Cancer Center, NY, USA
Robert Vonderheide, MD, DPhil
University of Pennsylvania, PA, USA
Sandra Demaria, MD
Weill Cornell Medical College, NY, USA
Jean-Luc Perfettini, MBBS
Institut Gustave Roussy, Paris, France
Lorenzo Galluzzi, PhD
Weill Cornell Medical College, NY, USA
Danielle M. Luissier, PhD
Washington University, St Louis, USA
Michele Mondini, PhD
Institut Gustave Roussy, Paris, France
Eric Deutsch, MD, PhD
Institut Gustave Roussy, Paris, France
Alexandre Boissonnas, PhD
Inserm CIMI, Paris, France
Erik Wennerberg, PhD
Weill Cornell Medical College, NY, USA
FRIDAY, September 22nd, 2017
William H. McBride, PhD, DSc
UCLA, CA, USA
David Brenner, PhD, DSc
Columbia University Medical Center, NY, USA
Silvia Formenti, MD
Weill Cornell Medical College, NY, USA
Peter Huber, MD
German Cancer Research Center DKFZ, Heidelberg, Germany
Joshua Brody, MD
Ruttenberg Treatment Center, NY, USA
Tim Illidge, BSc, PhD, MB, BS, DRCOG, MRCP, FRCP, FRCPath
Institute of Cancer Sciences, University of Manchester, UK
Ralph Weichselbaum, MD
University of Chicago, IL, USA
Paul Sondel, MD, PhD
University of Wisconsin, School of Medicine and Public Health, WI, USA
Chandan Guha, MBBS, PhD
Albert Einstein College of Medicine, NY, USA
Claire Vanpouille-Box, PhD
Weill Cornell Medical College, NY, USA
Karolina Palucka, MD, PhD
The Jackson Laboratory, CT, USA
Giorgio Trinchieri, MD
National Cancer Institute, MD, USA
Elizabeth Repasky, PhD
Roswell Park Cancer Institute, NY, USA
SATURDAY, September 23rd, 2017
Philippe Lambin, MD, PhD
